• Archives of Pharmacal Research
• /
• 제26권3호
• /
• pp.224-231
• /
• 2003

The anti-thrombotic effects of LB30057, a direct thrombin inhibitor, were evaluated with in vivo rat and dog thrombosis models. In rats, 1 mg/kg of LB30057 inhibited half of the clot formations in the inferior vena cava at 5 minutes after intravenous application. When measured at 2 hours after oral application, 100 mg/kg prevented approximately half of the clot formations in the inferior vena cava and 50 mg/kg prolonged the mean occlusion time from $15.6{\pm}1.3$ minutes to $47.2{\pm}8.3$ minutes in the carotid artery. In dogs, the formation of thrombus in the jugular vein was reduced to half at a dose range of 20-30 mg/kg at 6 hours after oral application. In addition, the LB30057 dosage required to reduce venous clot formation by approximately 80-90% in dogs was only about 10% of that required for the same reduction in rats. This is probably due to the variation in its time-dependent blood concentration profiles in each species; for example, the plasma half-life of LB71350 in dogs was longer than that in rats ($153.0{\pm}3.0$ vs. $129.7{\pm}12.7$ min at 30 mg/kg, i.v., respectively). AUG, $T_{max},{\;}G_{max}$, and BA in dogs were 59, 8.9, 9.17, and 13.3 times higher than those in rats at oral 30 mg/kg, respectively. Taken together, these results suggest that LB30057 administered orally is effective in the prevention of arterial and venous thrombosis in rats and dogs. It therefore represents a good lead compound for investigations to discover a new, orally available, therapeutic agent for treating thrombotic diseases.

• Journal of Trauma and Injury
• /
• 제28권4호
• /
• pp.232-240
• /
• 2015

Purpose: Thoracic aortic injury is a life-threatening injury that has been traditionally treated by using surgical management. Recently, thoracic endovascular aortic repair (TEVAR) has been conducted pervasively as a better alternative treatment method. Therefore, this study will focus on analyzing the outcome of TEVAR in patients suffering from a blunt thoracic aortic injury. Methods: Of the blunt thoracic aortic injury patients admitted to Eulji University Hospital, this research focused on the 11 patients who had received TEVAR during the period from January 2008 to April 2014. Results: Seven of the 11 patients were male. At the time of admission, the mean systolic pressure was $105.64{\pm}24.60mm\;Hg$, and the mean heart rate was $103.64{\pm}20.02per$ minute. The median interval from arrival to repair was 7 (4, 47) hours. The mean stay in the ICU was $21.82{\pm}16.37hours$. In three patients, a chimney graft technique was also performed to save the left subclavian artery. In one patient, a debranching of the aortic arch vessels was performed. In two patients, the left subclavian artery was totally covered. In one patient whose proximal aortic neck length was insufficient, the landing zone was extended by using a prophylactic left subclavian artery to left common carotid artery bypass before TEVAR. There were no operative mortalities, but a patient who was covered of left subclavian artery died from ischemic brain injury. Complications such as migration, endovascular leakage, collapse, infection and thrombus did not occur. Conclusion: Our short-term outcomes of TEVAR for blunt thoracic aorta injury was feasible. Left subclavian artery may be sacrificed if the proximal landing zone is short, but several methods to continue the perfusion should be considered.

• Tuberculosis and Respiratory Diseases
• /
• 제54권2호
• /
• pp.230-235
• /
• 2003

저자들은 폐색전증 의심하에 항응고제를 포함한 약물치료를 시행하였으나 임상증상의 호전이 없는 환자에서, 흉부 전산화단층촬영과 흉부 자기공명영상촬영을 통해 색전을 동반한 혈관의 종물을 발견한 후 수술적 제거로 진단한 원발성 폐동맥 육종 1예를 경험하였기에 문헌고찰과 함께 보고하는 바이다.

• Maxillofacial Plastic and Reconstructive Surgery
• /
• 제17권4호
• /
• pp.447-455
• /
• 1995

Cavernous sinus thrombosis is one of the major complications of abscesses of the maxillofacial region. The initial symptoms of CST are usually pain in the eye and tenderness to pressure. this is associated with high fluctuating fever, chills, rapid pulse, and sweating. Venous obstruction subsequently causes edema of the eyelids, lacrimation, proptosis, chemosis and retinal hemorrhages. Blindness is sometimes an accompaniment of cavernous sinus thrombosis when the infection also involves the orbit. There is also cranial nerve involvement (oculomotor, troclear, abducence) and ophthalmoplegia, diminished or absent corneal reflex, ptosis, and dilation of the pupil occur. The terminal stages bring signs of advanced toxemia and meningitis. Infections of the face can cause a septic thrombosis of the cavernous sinus. Furunculosis and infected hair follicles in the nose are frequent causes. Extractions of maxillary anterior teeth in the presence of acute infection and especially curettage of the sockets under such circumstances can cause this condition. The infection is usually staphylococcal. The inflection may spread directly through the pterygoid plexus of veins and the pterygomaxillary space and then ascend into the sinus or it may spread directly from the pterygopalatine space to the orbit. This is possible because of the absence of valves in the angular, facial, and ophthalmic veins. The treatment is empirical antibiotic therapy followed by specific anbibiotic therapy based on blood or pus culture. The inflection usually involves one side, however, it may easily spread to the opposite side through the circulus sinus. Unless it is treated early, the prognosis is poor even in this doses. Occasionally the antibiotics will not adequately resolve the septic thrombus, and death ensues. the use of anticoagulants to prevent venous thrombosis has been recommended, but the efficacy of such therapy has not been substantiated. Surgical access through eye enucleation has been suggested. We report a case which demonstrates cavernous sinus thrombosis by the infection after the functional neck dissection and the intraoral reconstruction with auriculomastoid fascio-cutaneous island flap.

• 한국임상약학회지
• /
• 제26권3호
• /
• pp.201-206
• /
• 2016

Objective: Direct current cardioversion for atrial fibrillation could be associated with the risk of thromboembolic events. Anticoagulation therapy with warfarin (INR 2.0-3.0) is recommended 3 weeks before and 4 weeks after cardioversion to reduce the risk of thromboembolism. This study evaluated warfarin therapy in pharmacist-managed anticoagulant services (ACS). Methods: This retrospective study was performed in 106 patients with atrial fibrillation from 2012 to 2013. The primary efficacy endpoint was the composite of stroke, transient ischemic attack, myocardial infarction, and cardiovascular death. The primary safety measure was major bleeding. To evaluate the peri-procedural effects of warfarin treatment, we studied whether target INR was maintained, as well as the maintenance period of the therapeutic range. Quality of treatment was measured by time in therapeutic range (TTR) by using the Rosendaal method. Results: There were no thromboembolic events, but TEE examination at time of cardioversion showed a left atrial thrombus in three patients (2.8%). Bleeding complications after cardioversion occurred in 2 patients (1.9%). The average INR value at the time of cardioversion was $2.59{\pm}0.8$, and was within the therapeutic range in 83 patients (78%). Analysis of the patients in whom the value was within the therapeutic range twice consecutively showed that the ratio of TTR was 80% and the therapeutic range was maintained in 67 patients (63%) for an average of 4.90 weeks prior to cardioversion. Similarly, 76 patients (72%) had a stable INR within the therapeutic range for an average of 5.70 weeks and a mean TTR of 83%. Conclusion: Pharmacists significantly contributed to appropriate warfarin treatment with close monitoring during cardioversion. Likewise, active pharmacist monitoring and systemic management should be considered to reduce thromboembolism and bleeding complications in the peri-cardioversion period.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권12호
• /
• pp.6257-6261
• /
• 2012

Objective: To investigate the safety and efficacy of transcatheter arterial chemoembolization (TACE), combined with portal vein embolization (PVE), and high intensity focused ultrasound (HIFU) sequential therapy in treating patients with hepatocellular carcinoma (HCC). Methods: Patients with inoperative HCC were treated by two methods: in the study group with TACE first, then PVE a week later, and then TACE+PVE every two months as a cycle, after 2~3 cycles finally HIFU was given; in the control group only TACE+PVE was given. Response (CR+PR), and disease control rate (CR+PR+SD), side effects, overall survival and time to progress were calculated. Results: Main side effects of both groups were nausea and vomiting. No treatment related death occurred. In the study group, 32 patients received TACE for overall 67 times, PVE 64 times, and HIFU 99 times; on average 2.1, 2 and 3.1 times for each patient, respectively. In the control group, 36 patients were given TACE 78 times and PVE 74 times, averaging 2.2 and 2.1 times per patient. Effective rate: 25.0% in study group and 8.3% in control group (p>0.05). Disease control rates were 71.9% and 44.4%, respectively (p<0.05). In patients with portal vein tumor thrombus, the rate reduced over 1/2 after treatment was 69.2%(9/13) in the study and 21.4%(3/14) in the control group (p<0.05). Rate of AFP reversion or decrease over 1/2 was 66.7%(16/24) in study and 37%(10/27) (p<0.05) in control group. Median survival time: 16 months in study and 10 months in control group. PFS was 7months in study and 3 months in control group. Log-rank test suggested that statistically significant difference exists between two groups (p=0.024). 1-, 2- and 3-year survival rates were 56.3%, 18.8% and 9.3% in study, while 30.6%, 5.6% and 0 in control group, respectively, with statistically significant difference between two groups (by Log-rank, p = 0.014). Conclusions: The treatment of TACE+PVE+HIFU sequential therapy for HCC increases response rate, prolong survival, and could thus be a safe and effective treatment for advanced cases.

• Investigative Magnetic Resonance Imaging
• /
• 제12권1호
• /
• pp.1-7
• /
• 2008

목적: 연조직종양의 조직 성분을 자기공명영상으로 평가하는데 MEDIC과 지방억제 T2 영상을 비교하여 더 나은 검사방법을 선택하고자 하였다. 대상 및 방법: 병리조직학적으로 진단된 연조직종양 10예 (신경집종 3예, 혈관종 2예, 지방종 1예, 혈관각화종 1예, 윤활막육종 1예, 지방육종 1예 그리고 악성섬유조직구종 1예)에서 25 조직 성분 (혈관 5예, 신경 4예, 섬유성 4예, 과세포성 4예, 출혈성괴사 2예, 낭성 2예, 지방성 2예, 점액버팀질 1예, 그리고 혈전 1예)을 선택하였다. 병리조직학적 조직 성분과 일치하는 동일 단면상을 가진 MEDIC과 지방억제 T2영상에 동일한 크기의 관심영역을 그려 불균질치를 얻었다. 불균질치는 영상의 불균질성을 나타내는 표준편차 값을 관심영역에서 얻은 신호강도 평균값으로 나눈 값으로 하였다. 결과: 25 조직 성분의 불균질치는 MEDIC 보다 지방억제 T2영상에서 높게 나타났다 (p < .001). 결론: MEDIC 영상은 불균질치가 현저히 낮으므로, 자기공명영상으로 연조직종양의 조직 성분을 평가하는데 지방억제 T2영상 보다 MEDIC 영상이 더 유용할 것으로 사료된다.

• Clinical and Experimental Pediatrics
• /
• 제45권11호
• /
• pp.1397-1402
• /
• 2002

목 적 : 대퇴동맥 혈전증은 하지 절단같은 극단적인 재앙뿐만 아니라 하지의 성장 장애를 초래할 수 있는 심도자술의 심각한 합병증이지만, 소아에서 이에 대한 표준적 치료법은 아직 정립되지 못한 상태이다. 저자는 심도자술후 발생한 대퇴동맥 혈전증에서 urokinase의 동맥내 국소 주입요법의 유용성을 검토하고자 본 연구를 시행하였다. 방 법 : 1994년 1월부터 2002년 8월까지 심도자술 후 발생한 대퇴동맥 혈전증으로 동아대학교병원 소아과에서 동맥내 urokinase 국소 주입법을 이용해 혈전용해술을 받은 9명, 12례를 대상으로 하여, 병력지와 혈관조영 소견을 후향적으로 분석하였다. 결 과 : 1) 대퇴동맥을 이용한 심도자술이 행해진 391례 중 전신적 헤파린 또는 urokinase에 반응을 보이지 않았던 대퇴동맥 혈전증의 발생빈도는 2.8퍼센트였다. 2) 대상 환아들의 연령은 기하평균 5.8개월(1-71개월)이었고 체중은 $8.5{\pm}4.6kg$(3.5-20.5 kg)였다. 3) Urokinase는 1,000-4,400 unit/kg/hr로 $50.6{\pm}29.2$시간(18-110시간)에 걸쳐 주입하였는데, 치료중 2례에서 환측의 천자부위로 출혈이 있었으며, 한명은 수혈이 필요했다. 심도자술후 4일 이내에 치료를 시작했던 환아들은 모두 혈전의 완전 소실을 보였다. 혈전 형성후 각각 12일과 19일째 치료를 시작했던 2례는 호전되지 않아 풍선 혈관성형술을 실시하였는데 부분적으로 도움이 되었다. 결 론: 심도자술후 발생한 대퇴동맥 혈전증에서, 전신적 혈전용해제 투여로 회복되지 않으면, 반대측 대퇴동맥을 통한 국소적 동맥내 혈전용해제 투여를 조기에 시행하는 것이 효과적이다.

• Journal of Chest Surgery
• /
• 제32권1호
• /
• pp.70-74
• /
• 1999

승모판의 기계판막치환술 후 판막이나 좌심방 내 혈전증은 판막 기능장애나 혈전색전증을 일으킨다. 조기 진단과 적절한 치료는 중요하지만 임상에서 쉽지 않다. 혈전용해 치료는 혈전증으로 인한 재수술의 위험성을 줄일 수 있어 혈전증 치료에 적절한 한 방법이 될 수 있다. 본 보고는 저분자량 헤파린과 와파린으로 혈전용해 치료를 한 3명의 환자를 보고하고자 하였다. 한 명의 임산부를 포함한 2명의 환자는 판막 혈전증으로 인한 판막폐쇄와 개폐운동 장애가 있었고 다른 한 명은 내원 5일전 혈전색전증으로 뇌경색이 발생한 좌심방내 혈전증 환자였다. 환자들은 프락시파린 0.3cc (7,500 ICU AXa)을 하루에 2∼3번씩 피하로 투여하여 치료를 받았다. 퇴원 당시 판막과 좌심방 내 혈전은 완전히 혹은 거의 완전히 용해되었고 판막의 개폐운동은 정상이었다. 혈전용해 때부터 외래 추적 기간동안 특별한 부작용은 없었다.

• 대한한방부인과학회지
• /
• 제19권1호
• /
• pp.31-46
• /
• 2006

Purpose : The Purpose of this research was to investigate the effects of antithromb otic activities of Honghwadangguisan(HDS) Methods : Measured the effect which was given to blood flow rate through the regular volume of glass tube after the blood was diluted five times with ACD soulution. Antithrombotic effect was calculated as a percentage of the experimental animal figure protected from the paralysis of hind legs or death of the mouse that is caused from the administration of platelet aggregation regent. Each of the groups consisted in 8 mice, was divided into Normal, Control, and HBS. All of these 3 group were supplied a saline solution and after an hour the control group brought the dextran extravasated blood. Also the HDS group was dosed to the experimental mice with Oral Zonde one day before the experiment. After that, the mice were abstained from food. And then we gave a measured amount of it before an hour. Finally, it gave rise to dextran extravasated blood as well as the Control group. Results : The results were obtained as follows. In vitro, HDS inhibited platelet aggregation induced by ADP and epinephrine significantly as compared with the control group. HDS showed fibrinolytic activity insignificantly as compared with the control group. HDS reduced blood flow rate in significantly as compared with the control group. In vivo HDS inhibited pulmonary embolism induced by collagen and epinephrine (inhibitive rate 50%). HDS increased number of platelet, fibrinogen amount and shortened prothrombin time, activated partial thromboplastin time significantly but reduced blood flow rate insignificantly as compared with the control group in thrombus model induced by dextran. Conclusion : HDS is effective antithrombotic activity from experimental result.